首页> 外文期刊>Neuro-Oncology >Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas
【24h】

Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas

机译:原发性中枢神经系统和淋巴结弥漫性大B细胞淋巴瘤中微RNA差异表达

获取原文
获取原文并翻译 | 示例
           

摘要

Most primary CNS lymphomas (PCNSL) are diffuse large B-cell lymphomas (DLBCL). However, clinical behavior and prognosis differ considerably from those for nodal DLBCL (nDLBCL), and their pathogenesis is still not fully understood. Micro-RNAs (miRNAs) have been associated with cancer development and progression. We investigated a large miRNA panel for differential expression in PCNSL and nDLBCL, to determine new mechanisms potentially involved in PCNSL pathogenesis. Using paraffin-embedded biopsy specimens from 21 HIV-negative patients with newly diagnosed PCNSL (n = 11) and nDLBCL (n = 10), we measured the expression of 365 miRNA species by quantitative real-time PCR using low-density PCR arrays. We found that 18 miRNAs were differentially expressed: median expression levels of 13 miRNAs were 2.1-13.1 times higher in PCNSL, and median expression levels of 5 miRNAs were 2.6-3.3 times higher in nDLBCL. MiRNAs upregulated in PCNSL were associated with the Myc pathway (miR-17-5p, miR-20a, miR-9), with blocking of terminal B-cell differentiation (miR-9, miR-30b/c), or with upregulation by inflammatory cytokines (miR-155). Putative tumor-suppressor miRNAs (miR-199a, miR-214, miR-193b, miR-145) were downregulated in PCNSL. There was no overlap of miRNAs dysregulated in PCNSL with those differentially expressed between immunohistologically defined germinal center B cell-like (GCB) and non-GCB types or, apart from miR-9, with miRNAs known to be over-expressed in human brain. We conclude that PCNSL exhibits a distinct pattern of miRNA expression compared with nDLBCL. This argues for the involvement of different molecular mechanisms in the pathogenesis of these two lymphoma types.
机译:大多数原发性CNS淋巴瘤(PCNSL)是弥漫性大B细胞淋巴瘤(DLBCL)。但是,其临床行为和预后与结节性DLBCL(nDLBCL)的临床行为和预后有很大不同,其发病机理仍未完全了解。微小RNA(miRNA)与癌症的发生和发展有关。我们调查了一个大型的miRNA面板,用于PCNSL和nDLBCL中的差异表达,以确定可能参与PCNSL发病机制的新机制。使用来自21位新诊断的PCNSL(n = 11)和nDLBCL(n = 10)的HIV阴性患者的石蜡包埋的活检标本,我们通过使用低密度PCR阵列的定量实时PCR测量了365种miRNA的表达。我们发现差异表达了18个miRNA:在PCNSL中13个miRNA的中位表达水平高2.1-13.1倍,在nDLBCL中5个miRNA的中位表达水平高2.6-3.3倍。在PCNSL中上调的miRNA与Myc途径(miR-17-5p,miR-20a,miR-9),阻断终末B细胞分化(miR-9,miR-30b / c)或通过炎性细胞因子(miR-155)。在PCNSL中,假定的肿瘤抑制miRNA(miR-199a,miR-214,miR-193b,miR-145)被下调。没有在PCNSL中失调的miRNA与免疫组织学定义的生发中心B细胞样(GCB)和非GCB类型之间差异表达的miRNA重叠,或者除了miR-9外,与已知在人脑中过度表达的miRNA没有重叠。我们得出的结论是,与nDLBCL相比,PCNSL展现出独特的miRNA表达模式。这表明在这两种淋巴瘤类型的发病机理中涉及不同的分子机制。

著录项

  • 来源
    《Neuro-Oncology》 |2011年第10期|p.1090-1098|共9页
  • 作者单位

    Medical Clinic for Hematology and Oncology, Charite Universitatsmedizin, Berlin, Germany,Department of Hematology and Oncology, Charite Universitatsmedizin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany;

    Institute of Pathology, Charite Universitatsmedizin, Berlin, Germany;

    Medical Clinic for Hematology and Oncology, Charite Universitatsmedizin, Berlin, Germany;

    Institute of Pathology, Charite Universitatsmedizin, Berlin, Germany;

    Institute of Pathology, Charite Universitatsmedizin, Berlin, Germany;

    Medical Clinic for Hematology and Oncology, Charite Universitatsmedizin, Berlin, Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    micro-RNA, Myc, primary CNS lymphoma;

    机译:微小RNA;Myc;原发性CNS淋巴瘤;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号